Kendra Adams - 18 Sep 2025 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Financial Officer
Signature
/s/ Shagha Russell, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
18 Sep 2025
Net transactions value
-$9,213
Form type
4
Filing time
19 Sep 2025, 16:13:49 UTC
Previous filing
18 Feb 2025
Next filing
18 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Adams Kendra Chief Financial Officer C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN /s/ Shagha Russell, Attorney-in-Fact 19 Sep 2025 0001991929

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Options Exercise $0 +6,250 +3.9% $0.000000 165,117 18 Sep 2025 Direct F1
transaction CCCC Common Stock Tax liability $9,213 -2,775 -1.7% $3.32 162,342 18 Sep 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on September 19, 2023.
F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.